|
WUMC Cancer and Leukemia Group B
|
5U10CA077440-14
|
$330,937
|
$62,878
|
BARTLETT, NANCY
|
WASHINGTON UNIVERSITY
|
|
Virginia Mason Community Clinical Oncology Program
|
2U10CA035192-27A1
|
$569,700
|
$108,243
|
Nichols, Craig
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
VCU Minority-Based Community Clinical Oncology Program
|
3U10CA052784-21S1
|
$50,000
|
$9,000
|
roberts, john
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
VCU Minority-Based Community Clinical Oncology Program
|
5U10CA052784-21
|
$490,679
|
$88,322
|
roberts, john
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
2P30CA014089-36
|
$6,160,984
|
$61,610
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-36S1
|
$50,000
|
$500
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-36S2
|
$244,500
|
$2,445
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-36S3
|
$74,923
|
$749
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
UPSTATE CAROLINA COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA035119-27
|
$1,400,911
|
$266,173
|
BEARDEN, JAMES
|
SPARTANBURG REGIONAL MEDICAL CENTER
|
|
UNMC Eppley Cancer Center Support Grant
|
2P30CA036727-25
|
$1,504,111
|
$60,164
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
UNMC Eppley Cancer Center Support Grant
|
3P30CA036727-25S1
|
$74,642
|
$2,986
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
University of Texas SPORE in Lung Cancer
|
5P50CA070907-14
|
$2,185,000
|
$109,250
|
MINNA, JOHN
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
|
University of Rochester Cancer Center CCOP Research Base
|
5U10CA037420-27
|
$2,137,632
|
$1,261,203
|
Morrow, Gary
|
UNIVERSITY OF ROCHESTER
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
3P30CA046592-23S2
|
$50,000
|
$500
|
WICHA, MAX
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
3P30CA046592-23S3
|
$5,694,947
|
$56,949
|
WICHA, MAX
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
University of Colorado Southwest Oncology Group
|
5U10CA042777-24
|
|
$0
|
ELIAS, ANTHONY
|
UNIVERSITY OF COLORADO DENVER
|
|
University of California, Irvine Cancer Center Support Grant
|
3P30CA062203-16S1
|
$74,361
|
$1,487
|
MEYSKENS, FRANK
|
UNIVERSITY OF CALIFORNIA IRVINE
|
|
University of California, Irvine Cancer Center Support Grant
|
5P30CA062203-16
|
$1,249,323
|
$24,986
|
MEYSKENS, FRANK
|
UNIVERSITY OF CALIFORNIA IRVINE
|
|
Understanding the biology of taxane response in the context of ETS rearranged pro
|
5R21CA143496-02
|
$142,619
|
$142,619
|
Rickman, David
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
|
Understanding resistance to HER family tyrosine kinase inhibitors
|
5R01CA122216-05
|
$246,252
|
$61,563
|
MOASSER, MARK
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
U10 Full Member Application Affiliated with SWOG
|
5U10CA105409-08
|
$325,684
|
$192,154
|
Kim, Edward
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Tumor -Targeting Chemotherapeutic Agents
|
5R01CA103314-20
|
$314,565
|
$314,565
|
OJIMA, IWAO
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
Transport of Large Molecules and Viral Vectors in Tumors: Effects of Cytotoxic an
|
5R01CA098706-08
|
$278,762
|
$278,762
|
BOUCHER, YVES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Transgenic Models for Prostate and Breast Cancer
|
ZIA BC 005740
|
$810,485
|
$16,209
|
Green, Jeffrey
|
CCR (NCI)
|
|
Total Synthesis and Biosynthesis of Bioactive Substances
|
5R01CA070375-15
|
$237,949
|
$118,975
|
WILLIAMS, ROBERT
|
COLORADO STATE UNIVERSITY-FORT COLLINS
|
|
TOLEDO COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA035415-28
|
$797,203
|
$111,608
|
MOWAT, REX
|
TOLEDO COMMUNITY HOSPITAL ONCOLOGY PROG
|
|
To establish the BC Cancer Agency - Vancouver Centre as a major SWOG centre
|
5U10CA142559-02
|
$188,304
|
$111,099
|
BLANKE, CHARLES
|
BRITISH COLUMBIA CANCER AGENCY
|
|
Therapeutic Targeting Agents for Ovarian Cancer
|
3R01CA115483-07S1
|
$58,992
|
$29,496
|
LAM, KIT
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
Therapeutic Targeting Agents for Ovarian Cancer
|
5R01CA115483-07
|
$299,038
|
$149,519
|
LAM, KIT
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
5P50CA083639-12
|
$2,117,925
|
$127,076
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
The Role of t-Darpp in Esophageal Adenocarcinoma
|
5R01CA133738-03
|
$226,980
|
$113,490
|
EL-RIFAI, WAEL
|
VANDERBILT UNIVERSITY
|
|
The role of SGK1 in triple-negative breast cancer resistance to treatment
|
5R21CA149472-02
|
$215,631
|
$215,631
|
Conzen, Suzanne
|
UNIVERSITY OF CHICAGO
|
|
The NFkB-dependent Secretome and Invasion/Angiogenesis in Thyroid Cancer
|
1R01CA155512-01A1
|
$305,422
|
$152,711
|
HAUGEN, BRYAN
|
UNIVERSITY OF COLORADO DENVER
|
|
The Gulf Coast MBCCOP
|
5U10CA128536-05
|
$484,872
|
$67,882
|
BEEKER, THADDEUS
|
PROVIDENCE HOSPITAL (MOBILE, AL)
|
|
The Evaluation of Novel Therapeutics for Genitourinary Malignancies
|
ZIA SC 010098
|
$359,440
|
$17,972
|
Dahut, William
|
CCR (NCI)
|
|
The Brooklyn Minority-Based Community Clinical Oncology Program
|
3U10CA114671-05S1
|
$49,979
|
$8,996
|
Solomon, William
|
SUNY DOWNSTATE MEDICAL CENTER
|
|
The Brooklyn Minority-Based Community Clinical Oncology Program
|
3U10CA114671-05S2
|
$139,741
|
$25,153
|
Solomon, William
|
SUNY DOWNSTATE MEDICAL CENTER
|
|
The Brooklyn Minority-Based Community Clinical Oncology Program
|
5U10CA114671-05
|
$518,164
|
$93,270
|
Solomon, William
|
SUNY DOWNSTATE MEDICAL CENTER
|
|
The Bcl-2-p85/PI3K signaling axis
|
5R01CA140980-02
|
$384,435
|
$192,218
|
ZHANG, XIAO-KUN
|
SANFORD-BURNHAM MEDICAL RESEARCH INSTIT
|
|
Telomeres, telomerase and chemotherapy: Bench to bedside
|
5R01CA077091-08
|
$1
|
$1
|
Au, Jessie
|
OPTIMUM THERAPEUTICS, LLC
|
|
Taxol: Mechanisms of Action and Resistance
|
5R01CA077263-11
|
$402,550
|
$402,550
|
HORWITZ, SUSAN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Taxane Resistance in Breast and Ovarian Cancer Cells
|
5R01CA114037-05
|
$288,798
|
$288,798
|
SIKIC, BRANIMIR
|
STANFORD UNIVERSITY
|
|
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER
|
5R01CA123159-05
|
$270,405
|
$270,405
|
COLE, DAVID
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Targeting Notch, PI3K-AKT and other novel pathways in breast cancer stem cells
|
7R01CA138197-04
|
$446,311
|
$44,631
|
CHANG, JENNY
|
METHODIST HOSPITAL RESEARCH INSTITUTE
|
|
Targeting CDK5 in Pancreatic Cancer: Mechanistic and Preclinical Development
|
5R01CA134767-04
|
$330,091
|
$82,523
|
NELKIN, BARRY
|
JOHNS HOPKINS UNIVERSITY
|
|
TARGETED INTERVENTION OF BREAST ONCOGENIC PATHWAYS
|
5R01CA098473-07
|
$310,044
|
$77,511
|
SEBTI, SAID
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Synthetic Studies Related to Cancer Research/Treatment
|
4R37CA031845-31
|
$423,345
|
$105,836
|
WENDER, PAUL
|
STANFORD UNIVERSITY
|
|
Synthesis, Biosynthesis, and Structure of Antitumor Agents
|
5R01CA076497-12
|
$59,990
|
$14,998
|
HOYE, THOMAS
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
|
Synergistic chemo-siRNA combination therapy
|
1R01CA158300-01
|
$372,483
|
$372,483
|
WIENTJES, M
|
OPTIMUM THERAPEUTICS, LLC
|
|
Surface-modified pharmaceutical nanocarriers for subcellular targeting
|
5R01CA128486-04
|
$300,503
|
$150,252
|
TORCHILIN, VLADIMIR
|
NORTHEASTERN UNIVERSITY
|
Total relevant funding to Taxol for this search: $70,884,268
|